Prevention of HIV for persons with low-frequency, high-risk exposures: PrEP (preexposure prophylaxis), PEP (postexposure prophylaxis), or 'PIP' (postexposure prophylaxis in-pocket)

Brian R Wood^{1

2}

Affiliations

Brian R Wood. AIDS. 2020.

. 2020 Mar 1;34(3):481-482.

doi: 10.1097/QAD.0000000000002446.

Brian R Wood^{1

2}

No abstract available

References

1. Chou R, Evans C, Hoverman A, Sun C, Dana T, Bougatsos C, et al. Preexposure prophylaxis for the prevention of HIV infection. Evidence report and systematic review for the US Preventive Services Task Force. JAMA 2019; 321:2214–2230.
1. Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. ANRS IPERGAY Study Group. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med 2015; 373:2237–2246.
1. Antoni G, Tremblay C, Charreau I, Cua E, Rojas-Castro D, Hall N, et al. On-demand PrEP with TDF/FTC remains highly effective among MSM with infrequent sexual intercourse: a sub-study of the ANRS IPERGAY trial. In: 9th International AIDS Society Conference, Paris, Abstract TUACO102, July 2017.
1. Centers for Disease Control and Prevention: US Public Health Service: Preexposure prophylaxis for the prevention of HIV infection in the United States—2017 Update: a clinical practice guideline. Available at: https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf. Published March 2018. (Accessed 5 November 2019)
1. Saag MS, Benson CA, Gandhi RT, Hoy JF, Landovitz RJ, Mugavero MJ, et al. Antiretroviral drugs for treatment and prevention of HIV Infection in Adults: 2018 recommendations of the international antiviral society-USA panel. JAMA 2018; 320:379–396.